Drug Profile
Research programme: anti-cancer immunotherapies - ImmunoMet Therapeutics
Alternative Names: IM-184; IM-188Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator ImmunoMet Therapeutics
- Class Antineoplastics; Biguanides; Small molecules
- Mechanism of Action Immunostimulants; Mitochondrial oxidative phosphorylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer